WO2000005369A2 - Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis - Google Patents
Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis Download PDFInfo
- Publication number
- WO2000005369A2 WO2000005369A2 PCT/US1999/012839 US9912839W WO0005369A2 WO 2000005369 A2 WO2000005369 A2 WO 2000005369A2 US 9912839 W US9912839 W US 9912839W WO 0005369 A2 WO0005369 A2 WO 0005369A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleotide
- polynucleotide
- protein
- amino acid
- sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 165
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 162
- 125000003275 alpha amino acid group Chemical group 0.000 title claims description 30
- 230000033115 angiogenesis Effects 0.000 title abstract description 31
- 108091028043 Nucleic acid sequence Proteins 0.000 title description 8
- 239000002773 nucleotide Substances 0.000 claims description 118
- 125000003729 nucleotide group Chemical group 0.000 claims description 118
- 102000040430 polynucleotide Human genes 0.000 claims description 102
- 108091033319 polynucleotide Proteins 0.000 claims description 102
- 239000002157 polynucleotide Substances 0.000 claims description 102
- 210000004027 cell Anatomy 0.000 claims description 60
- 238000000034 method Methods 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 24
- 230000004071 biological effect Effects 0.000 claims description 23
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 230000003511 endothelial effect Effects 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000003190 augmentative effect Effects 0.000 claims 4
- 150000007523 nucleic acids Chemical group 0.000 abstract description 12
- 230000003527 anti-angiogenesis Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 130
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 27
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 27
- 230000002491 angiogenic effect Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 101100323232 Mus musculus Ang3 gene Proteins 0.000 description 17
- 210000002216 heart Anatomy 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000003102 growth factor Substances 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- -1 and derivatives Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 10
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 9
- 229940126864 fibroblast growth factor Drugs 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 108020004635 Complementary DNA Proteins 0.000 description 7
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 7
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 7
- 230000001772 anti-angiogenic effect Effects 0.000 description 7
- 238000010804 cDNA synthesis Methods 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000036530 EDG receptors Human genes 0.000 description 6
- 108091007263 EDG receptors Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000007998 vessel formation Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 108010009906 Angiopoietins Proteins 0.000 description 3
- 102000009840 Angiopoietins Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 102400000068 Angiostatin Human genes 0.000 description 2
- 108010079709 Angiostatins Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102100038664 Fibrinogen-like protein 1 Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 108060008245 Thrombospondin Proteins 0.000 description 2
- 102000002938 Thrombospondin Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000008247 brain infarction Diseases 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000033458 reproduction Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 102000009075 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 101710197507 Fibrinogen-like protein 1 Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924546 Homo sapiens Angiopoietin-related protein 7 Proteins 0.000 description 1
- 101001031635 Homo sapiens Fibrinogen-like protein 1 Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 101100434911 Mus musculus Angpt1 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150012195 PREB gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- OIBDVHSTOUGZTJ-PEBLQZBPSA-N [(2r,3r,4s,5s,6s)-3,4,6-triacetyloxy-5-(trifluoromethylsulfonyloxy)oxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@@H](OS(=O)(=O)C(F)(F)F)[C@@H](OC(C)=O)[C@@H]1OC(C)=O OIBDVHSTOUGZTJ-PEBLQZBPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000437 effect on angiogenesis Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 108091007231 endothelial receptors Proteins 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000016021 phenotype Diseases 0.000 description 1
- 150000004633 phorbol derivatives Chemical class 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000026341 positive regulation of angiogenesis Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
Definitions
- the present invention provides novel amino acid sequences of potent angiogenesis/anti- angiogenesis secreted proteins and polynucleotide sequences encoding such proteins, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins, and derivatives, fragments and analogs thereof.
- angiogenesis i.e., generation of new blood vessels into a tissue or organ, only in restricted situations.
- endothelial cells react to stimulation with finely tuned signaling responses.
- the "endothelium” is a thin layer of flat epithelial cells that lines serous cavities, lymph vessels, and blood vessels.
- neovascularization is controlled by a balance of stimulatory and inhibitory angiogenic factors.
- ischemic heart disease ischemic peripheral vascular disease
- tumor growth and metastasis reproduction, embryogenesis, wound healing, bone repair, rheumatoid arthritis, diabetic retinopathy and other diseases (for review, see e.g. Battegay, 1995).
- Endothelial cells and pericytes surrounded by a basement membrane, form capillary blood vessels.
- Angiogenesis begins with the erosion of the basement membrane by enzymes released by endothelial cells and leukocytes.
- the endothelial cells which line the lumen of blood vessels, then protrude through the basement membrane.
- Angiogenic stimulants induce the endothelial cells to migrate through the eroded basement membrane.
- the migrating cells form a "sprout" off the parent blood vessel, where the endothelial cells undergo mitosis and proliferate.
- the endothelial sprouts merge with each other to form capillary loops, creating the new blood vessel.
- Persistent, unregulated angiogenesis occurs in a multiplicity of disease states, tumor metastasis and abnormal growth by endothelial cells and supports the pathological damage seen in these conditions.
- the diverse pathological disease states in which unregulated angiogenesis is present have been grouped together as angiogenic dependent or angiogenic associated diseases.
- angiogenesis regulators control the fate of vascular wall cells. They remain either in a state of vascular homeostasis, or they proceed to neovascularization, e.g., tumor growth and the switch to an angiogenic tumor pheno type correlates with increased secretion of angiogenic molecules such as fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and others.
- FGF fibroblast growth factor
- VEGF vascular endothelial growth factor
- tumors also acquire a more angiogenic phenotype because inhibitors of angiogenesis are down-regulated during turnorigenesis (e.g. thrombospondin)(Dameron et al., 1994, Science 265:1582-1584).
- Angiogenic and antiangiogenic (or angiostatic) molecules control the formation of new vessels via different mechanisms.
- Antiangiogenic molecules, or angiogenesis inhibitors e.g. angiostatin, angiopoeitin-1 (Angl 1), rat microvascular endothelial differentiation gene (MEDG), somatostatin, thrombospondin. platelet factor 4
- angiogenesis inhibitors can repress angiogenesis, and therefore, maintain vascular homeostasis (see, e.g. for review Bicknell, 1994, Ann. Oncol. 5 (suppl) 4:45- 50).
- Angiogenic molecules are capable of inducing the formation of new vessels and include, for example, but not for limitation, fibroblast growth factor (FGF), angiopoeitin 2 (Ang-2), erythroipoietin, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and others (for review, see e.g. Folkman & Shing, 1992, J. Biol. Chem. 267: 10931-10934). FGF elicit its effects mainly via direct action on relevant endothelial cells via its endothelial receptor (e.g. Folkman & Shing, 1992. J. Biol. Chem. 267:10931-10934). FGF lacks a signal sequence for secretion.
- FGF fibroblast growth factor
- Ang-2 angiopoeitin 2
- HGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- FGF elicit its effects mainly via direct action on
- Angiogenesis has been implicated in ischemic heart and ischemic vascular disease. In myocardial infarction new vessels penetrate the necrotic area and the surrounding schemic tissue.
- Neovascularizations together with inflammatory cells, remove cellular debris and play a role in tissue repair and remodeling that results in myocardial scar formation.
- FGF-induced mycoardial infarction and neovascularization show that angiogenesis contributes to the preservation of ischemic tissue and myocardial pump function in myocardial necrosis. This . suggests a therapeutic use of angiogenic factors in clinical situations.
- angiogenesis has been implicated in various cancers.
- Angiogenesis is an essential component of the metastatic pathway (see, e.g. Zetter, 1998, Ann. Rev. Med. 49:407- 427). These blood vessels provide the principal pathway by which rumor cells exit the primary tumor site and enter the circulation.
- Tumor angiogenesis is regulated by the production of angiogenic stimulators including members of the FGF and VEGF families (see, e.g. Fernig & Gallaher, 1994, Prog. Growth Factor Res. 5:353-377). Tumors may also activate angiogenic inhibitors such as angiostatin (U.S.
- Angiopoietin-1 is an angiogenic factor that signals through the endothelial cell- specific Tie2 receptor tyrosine kinase.
- Ang-1 is essential for normal endothelial developmental processes in the mouse (Davis et al., 1996, Cell 87: ).
- Ang-1 induces the formation of capillary sprouts (Koblizek et al., 1998, Curr. Biol. 8:529-532).
- the protein is expressed only on endothelial cells and early hemopoietic cells (e.g., see Suri et al., 1996, Cell 87:1171-1180).
- Angiopoietin-2 (Ang-2) is a naturally occurring antagonist for Angl and Tie2 and can disrupt blood vessel formation in the mouse embryos (see, eg. Maisonpierre et al., 1997, Science 277:55-). Ang-2 is expressed only at sites of vascular remodeling. In animal models some angiogenesis-dependent diseases can be controlled via induction or inhibition of new vessel formation. Treatment of diseases by modulation of angiogenesis are currently tested in clinical trials. Thus the manipulation of new vessel formation in angiogenesis- dependent conditions such as wound healing, inflammatory diseases, ischemic heart and peripheral vascular disease, myocardial infarction, diabetic retinopathy, and cancer is likely to create new therapeutic options.
- angiogenesis is believed to play a significant role in the metastasis of a cancer and in the ischemic heart and ischemic vascular disease. If this angiogenic activity could be repressed or eliminated, then the tumor, although present, would not grow. In the disease state, prevention of angiogenesis could avert the damage caused by the invasion of the new microvascular system. If this angiogenic activity could be stimulated or induced, ischemic tissues in the heart and brain and mycocardial necrosis could be prevented. In the disease state, stimulation or induction of angiogenesis could avert the damage. Therapies directed at control of the angiogenic processes could lead to the abrogation or mitigation of these diseases.
- compositions and methods of this invention are useful in inhibiting the activity of endogenous growth factors in premetastatic tumors and preventing the formation of the capillaries in the tumors thereby inhibiting the growth of the tumors.
- the composition, and antibodies specific to the composition should also be able to modulate the formation of capillaries in other angiogenic processes, such as wound healing and reproduction.
- the composition and method for inhibiting angiogenesis should preferably be non-toxic and produce few side effects.
- compositions and methods of this invention are useful in stimulating the growth of blood vessels, especially in mycocardial infarction and other heart diseases or brain infarcts (strokes).
- the composition should be able to overcome the necrotic effects of ischemic tissue and thereby prevent the effects of heart diseases or strokes.
- the composition and method for stimulating angiogenesis should preferably be non-toxic and produce few side effects.
- angiopoeitin-3 novel molecules, referred to herein as "angiopoeitin-3
- Ang-3 human microvascular endothelial differentiation gene 1 (hMEDGl)” and “heart specific growth factor-8b (FGF-8b)” polypeptides, as well as nucleic acid sequences encoding those molecules.
- the novel nucleic acid sequences of this invention is operatively linked to one or more expression control sequences.
- the invention also provides a host cell, including bacterial, plant, yeast, insect and mammalian cells, that produce the novel polypeptides, whether the cell is transformed with the nucleic acid sequences encoding those proteins, or whether the cell is transformed with regulatory sequences to activate or enhance production of these proteins from an endogenous nucleic acid sequence encoding same.
- Processes are also provided for producing a protein, which comprise growing a culture of host cells producing such proteins (as described above) in a suitable culture medium, and purifying the protein from the culture.
- the protein produced according to such methods is also provided by the present invention.
- the protein comprises an angiopoeitin-3, hMEDGl and FGF-8b amino acid sequence or fragments thereof, the protein being substantially free from other mammalian proteins.
- Such compositions may further comprise a pharmaceutically acceptable carrier.
- Compositions comprising an antibody which specifically reacts with such protein are also contemplated by the present invention.
- Methods are also contemplated for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.
- compositions and methods of this invention are useful in anti-cancer and heart disease therapies. Diagnostic, prognostic and screening kits are also contemplated. BRIEF DESCRIPTION OF THE DRAWINGS
- FIG. 1 depicts the nucleotide sequence and deduced amino acid sequence of angiopoeitin-3 (Ang-3). The signal sequence is underlined.
- FIG. 2 depicts the nucleotide sequence and deduced amino acid sequence of hMEDGl.
- the signal sequence is underlined.
- FIG. 3 depicts the nucleotide sequence and deduced amino acid sequence of heart specific growth factor 8b (FGF-8b).
- Panel A shows the preliminarily determined sequence, with the signal sequence underlined.
- Panel B shows the confirmed sequence.
- direct angiogenic/antiangiogenic molecules means a molecule that elicits an effect on angiogenesis/antiangiogenesis in vivo upon exogenous administration or overexpression, that has an effect on relevant endothelial cells in vitro that is compatible with angiogenesis/antiangiogenesis. and the role of the molecule has been established in a process or disease.
- This invention further provides for novel angiopoeitin-3, hMEDGl, or FGF-8b proteins and genes encoding those proteins, as well as contemplating derivatives, homologs, active fragments and analogs, from various species, particularly vertebrates, and more particularly mammals.
- the foregoing proteins and genes are of human origin. Production of the foregoing proteins and derivatives, e.g., by recombinant methods, is also contemplated in the present invention.
- the fragment, derivative or analog is functionally active, i.e.. capable of exhibiting one or more functional activity associated with wild type Ang3, hMEDGl . or FGF-8b protein.
- Such functional activities include, but are not limited to, the stimulation or inhibition of angiogenesis and related disorders and the treatment of heart disease and related disorders.
- Such functional activities include further, but are not limited to, antigenicity [ability to bind (or compete with Ang-3, hMEDGl, or FGF-8b for binding) to an anti-Ang3, anti-hMEDGl. or anti-FGF-8b antibody, respectively], immunogenicity (ability to generate an antibody that binds to anti-IP-Ang3, anti-IP-hMEDGT, or anti-IP-heart specific growth factor, respectively), etc.
- RNA messenger RNA
- Clontech e.g., Fetal brain, heart, kidney, fetal liver, liver, lung, skeletal muscle, pancreas and placenta
- Oligotex TM cDNA synthesis kit QIAGEN, Inc.; Chatsworth, CA
- E. coli DNA polymerase and 3.5 units of E. coli RNase H (all supplied by BRL; Grand Island, NY), second-strand synthesis was performed at 16°C for 2 hours. Five units of T 4 DNA polymerase was then added, and incubation was continued for an additional 5 minutes at 16°C. The reaction was then treated with 5 units of arctic shrimp alkaline phosphatase (U.S. Biochemicals; Cleveland OH) at 37°C for 30 minutes, and the cDNA was purified by standard phenol/chloroform (50:50 v/v) extraction. The yield of cDNA was estimated using fiuorometry with the Picogreen TM Labeling System (Molecular Probes; Eugene, OR).
- the double-stranded cDNA was digested with various restriction enzymes, ligated to linkers compatible with the over-hanging termini generated by the restriction digestion.
- the restriction fragments were amplified utilizing 30 cycles of polymerase chain reaction (PCR) by the addition of the following reagents: 2 ⁇ l 10 mM dNTP; 5 ⁇ l 10X TB buffer (500 mM Tris, 160 mM (NH4) : SO 4 ,; 20 mM MgC , pH 9.15); 0.25 ⁇ l Klentaq (Clontech Advantage) : PFU (Stratagene; La Jolla CA) in a 16: 1 v/v ratio; 32.75 ⁇ l ddH2O.
- PCR polymerase chain reaction
- TA TM cloning vector Invitrogen. Individual clones were subjected to dye-primer, double-stranded DNA sequencing utilizing PCR products which were derived from amplification using vector-specific primers, which flanked the insertion, site as templates. Sequencing was performed using a standard chemistry methdology on ABI Model 377 sequencers (Molecular Dynamics). 2. ISOLATED PROTEINS AND POLYNUCLEOTIDES, AND
- Ang-3 The sequence of a polynucleotide encoding an Ang-3 protein of the present invention is set forth in Figure 1, with the coding region extending from nucleotides 352 to 1824. This polynucleotide has been named "Angiopoeitin-3 (Ang-3)".
- Ang-3 The amino acid sequence of the protein encoded by Ang-3 is also shown in Figure 1.
- Ang-3 was isolated from a human heart library, cloned into a vector and sequenced by methods known in the art.
- the nucleic acid sequence in Figure 1 encodes a novel protein, Ang-3.
- Sequence homology algorithms e.g., BLASTN/BLASTX or FASTA searches, revealed no exact sequence matches.
- a BLASTX search revealed 59 % homology between Ang-3 (in the approximate region of nucleotides 1067 and 1833 of Figure 1), and human angiopoietin proteins (including human Angl [GenBank Accession Number U83508] and human Ang-2 [GenBank Accession Number AF004327].
- a BLASTP search also revealed 63 % homology between Ang-3 (in the approximate region of amino acids 269 to 491 of Figure 1), and human angiopoietin proteins (including human angiopoetin-like protein (CDT6 gene) [GenBank Accession Number Y16132]). Furthermore, a BLASTP search revealed 51 % homology between Ang-3 (in the approximate region of amino acids 8 to 491 of Figure 1), and mouse angiopoietin- 1 protein [GenBank Accession Number U83509]).
- Ang-3 in the approximate region of amino acids 277 to 491 of Figure 1
- fibrinogen-like proteins including fibrinogen-like protein 1 precursor [TREMBL Accession Number Q08830]), fibrinogen-related protein HFREP-1 precursor [PER. Accession Number JN0596] and fibrinogen-like protein [TREMBLAccession Number Q143114]).
- Ang-3 has a secretion signal peptide.
- Ang-1 and Ang-2 are 60 % identical.
- Ang-3 is homologous in the carboxy-terminal fibrinogen-like domain to Ang-1 and Ang-2 (Maisonpierre et al., 1997, Science 277:55-60). Based upon these homologies, Ang-3 and these homologous proteins are expected to share at least some activities.
- the present invention provides an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence shown m Figure 1 from nucleotide 352 to nucleotide 1824, or nucleotide 415 to nucleotide 1824;
- a polynucleotide comprising a fragment of the nucleotide sequence shown in Figure 1 encoding a protein having biological activity
- a polynucleotide encoding a protein comprising the amino acid sequence shown in Figure 1, from nucleotide 352 to nucleotide 1824 (i.e., including the signal sequence) or from nucleotide 415 to nucleotide 1824 (the mature peptide), herein called angiopoetin-3;
- hMEDGl The sequence of a polynucleotide encoding another protein of the present invention is set forth in Figure 2, with the coding region extending from nucleotides 190 to 858.
- This polynucleotide has been named "Microvascular Endothelial Differentiation Gene” (hMEDGl).
- the amino acid sequence of the protein encoded by the endothelial differentiation gene (hMEDGl) is set forth in Figure 2.
- HMEDGl was isolated from a human heart library, cloned into a vector and sequenced by methods known in the art.
- the nucleic acid sequence in Figure 2 encodes a novel protein, hMEDGl .
- Sequence homology algorithms e.g., BLASTN/BLASTX or FASTA searches revealed no exact sequence matches.
- a BLASTX search revealed 84 % homology between the hMEDGl protein (in the approximate region of nucleotides 56-1013 of Figure 2 and rat microvascular endothelial differentiation gene 1 (GenBank Accession Number X98993).
- BLASTP search revealed 94 % homology between the hMEDGl protein (in the approximate region of amino acids 51-223 of Figure 2) and rat microvascular endothelial differentiation gene 1 (SPTREMBL-Acc. No. P97554).
- hMEDGl contains 50 amino acids that were not reported in the rat MEDGl protein. These 50 amino acids comprise a signal sequence; therefore hMEDGl does encode a secreted factor. Based upon these homologies, hMEDGl and these homologous proteins are expected to share at least some activities.
- the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence shown in Figure 2 from nucleotide 51 to nucleotide 858, or from nucleotide 259 to nucleotide 858; (b) a polynucleotide comprising a fragment of the nucleotide sequence shown in Figure 2 encoding a protein having biological activity;
- the sequence of a polynucleotide encoding another protein of the present invention is set forth in Figure 3, with the coding region extending from nucleotides 39 to 618 (Panel A) and 39 to 659 (Panel B).
- This polynucleotide has been identified as "human heart specific fibroblast growth factor 8b (FGF-8b)"
- FGF-8b human heart specific fibroblast growth factor 8b
- the amino acid sequence of the protein encoded by FGF-8b is set forth in Figure 3.
- the human FGF-8b was isolated from a human heart library using a trap which selects for nucleotides encoding secreted proteins; therefore, FGF-8b encodes a secreted factor.
- the nucleic acid sequence in Figure 3 encodes a novel protein, FGF-8b.
- Panel A shows a preliminarily determined sequence.
- Panel B shows a confirmed sequence.
- Sequence homology algorithms e.g., BLASTN/BLASTX or FASTA searches revealed no exact sequence matches.
- a BLASTP search revealed about 80 % homology between the FGF-8b (particularly in the approximate region of amino acids 1-181 of Figure 3) and various human growth factors including fibroblast growth factor 8, androgen-induced growth factor, keratinocyte growth factor, heparin-binding growth factor- 1, and beta-endothelial cell growth factor (including without limitation those assigned accession numbers G2660747,
- the present invention provides a composition . comprising an isolated polynucleotide selected from the group consisting of:
- the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
- Nucleic acids encoding Ang3, hMEDGl, or FGF-8b can be obtained by any method known in the art. e.g, by PCR amplification using synthetic primers that hybridize to the 3' and 5' ends of the sequence and/or by cloning from a cDNA or genomic library using an oligonucleotide specific for the gene sequence, e.g., as described infra.
- Homologs e.g., of nucleic acids encoding Ang3, hMEDGl, or FGF-8b of species other than human, or other related sequences, e.g., paralogs, can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning, e.g., as described infra, for Ang3, hMEDGl, or FGF-8b nucleotide sequences.
- polynucleotides hybridizing to the polynucleotides of the present invention under stringent conditions and highly stringent conditions are also part of the present invention.
- Preferred high stringency conditions are hybridization in 4X SSC, 5X
- the isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991), in order to produce the protein recombinantly.
- an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991)
- Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990).
- operably linked means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
- Mammalian host cells include, for example, monkey COS cells.
- yeast eukaryotes
- prokaryotes such as bacteria.
- yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins.
- Potentially suitable bacterial strains include Escherichia coli, Bacillus subtilis. Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
- the protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
- suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
- Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif., U.S.A.
- an insect cell capable of expressing a polynucleotide of the present invention is "transformed.”
- Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention.
- Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H. U. Saragovi, et al, Bio/Technology 10, 773-778 (1992) and in R. S. McDowell, et al., J. Amer. Chem. Soc. 114, 9245-9253 (1992), both of which are incorporated herein by reference.
- Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.
- fragments of the protein may be fused through "linker" sequences to the Fc portion of an immuno globulin.
- a bivalent form of the protein such a fusion could be to the Fc portion of an IgG molecule.
- Other immunoglobulin isotypes may also be used to generate such fusions.
- a protein-IgM fusion would generate a decavalent form of the protein of the invention.
- the protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein.
- the resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography.
- the purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin- toyopearl R TM. or Cibacrom blue 3GA Sepharose RTM; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
- the protein of the invention may also be expressed in a form which will facilitate purification.
- it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New York.
- the protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope.
- One such epitope (“Flag") is commercially available from Kodak (New Haven, Conn.).
- RP-HPLC reverse-phase high performance liquid chromatography
- hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other aliphatic groups
- Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein.
- the protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein.”
- the protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
- the protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art.
- the synthetically-constructed protein sequences by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
- the proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered.
- modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques.
- Modifications of interest in the protein sequences may include the replacement, insertion or deletion of a selected amino acid residue in the coding sequence.
- one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Mutagenic techniques for such replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Pat. No. 4,518,584, incorporated by reference).
- polynucleotides of the present invention and the proteins encoded thereby are expected to exhibit one or more of the uses or biological activities identified below.
- Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
- the biological activity of the proteins of this invention can be assayed by any suitable method known in the art.
- the angiogenic/antiangiogenic potential can be characterized in angiogenesis assays in vivo such as the chick chorionic allantoic membrane (CAM) assay or different cornea micropocket assays (Klagsbrun & Folkman, 1990, In: Sporn & Roberts (eds). Peptide growth factors and their receptors II, pp. 549-574).
- An a in vivo angiogenesis assay is described in, eg., U.S. Pat. No. 5,382,514, incorporated by reference), and a mouse model of hindlimb ischemia was described by Couffinhal et al., 1998, Am.
- Assays for angiogenic/antiangiogenic activity include methods for inhibition of angiogenesis (see, for example, but not limited to, U.S. Pat. No. 5733876, 5639725, 5712291, 5698586, 5753230, 5733876, 5766591.5434185, 5721226,56293405593990, 5629327, 5744492, 5646136, 5610166, 5574026, 5567693, 5563130, each herein fully incorporated by reference).
- a protein of the present invention may exhibit angiogenic (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity.
- Many protein factors discovered to date including all known angiopoeitins and growth factors, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of angiogenic activity.
- the activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10,B9, B9/11, BaF3, MC9/G, M+(preB M+), 2E8, RB5, DAI, 123, Tl 165, HT2, CTLL2, TF-1, Mo7e and CMK.
- Methods of diagnosis, prognosis, and screening for diseases and disorders associated with aberrant levels of an Ang3, hMEDGl, or heart specific growth factor are contemplated.
- the invention also contemplates methods of treating or preventing diseases or disorders associated with aberrant levels of an Ang3, hMEDGl, or heart specific growth factor, or aberrant levels of activity of one or more of the components of the complex, comprising administration of the Ang3, hMEDGl, or heart specific growth factor.
- Methods of assaying an Ang3, hMEDGl, or FGF-8b, for activity as therapeutics or diagnostics as well as methods of screening modulators (i.e., inhibitors, agonists and antagonists) are also contemplated.
- a protein of the present invention may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubihzers, and other materials well known in the art.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.
- the pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment.
- protein of the present invention may be included in formulations of the particular Ang3, hMEDGl, or FGF-8b to minimize side effects of the Ang3, hMEDGl, or FGF-8b agent.
- protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection.
- a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection
- protein of the present invention will be in the form of a pyrogen-free, parenterally-acceptable aqueous solution.
- the preparation of such parenterally acceptable protein solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
- a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
- an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
- the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
- a protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins.
- pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
- the term "therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
- a meaningful patient benefit i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions.
- the term refers to that ingredient alone.
- the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
- a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated.
- Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing Ang3, hMEDGl, or heart specific growth factor.
- protein of the present invention may be administered either simultaneously with the Ang3, hMEDGl, or FGF-8b, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with Ang3, hMEDGl, or FGF-8b.
- the amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further.
- Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen.
- the peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH).
- KLH keyhole limpet hemocyanin
- Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein.
- Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved.
- neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
- Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
- Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced in vivo for therapeutic purposes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000561315A JP2002522019A (en) | 1998-07-20 | 1999-07-20 | Nucleotide and amino acid sequences of secreted proteins involved in angiogenesis |
AU50818/99A AU5081899A (en) | 1998-07-20 | 1999-07-20 | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
EP99935312A EP1098974A2 (en) | 1998-07-20 | 1999-07-20 | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
CA002335326A CA2335326A1 (en) | 1998-07-20 | 1999-07-20 | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9339798P | 1998-07-20 | 1998-07-20 | |
US60/093,397 | 1998-07-20 | ||
US15068498A | 1998-09-10 | 1998-09-10 | |
US09/150,684 | 1998-09-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000005369A2 true WO2000005369A2 (en) | 2000-02-03 |
WO2000005369A3 WO2000005369A3 (en) | 2000-06-15 |
Family
ID=26787485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/012839 WO2000005369A2 (en) | 1998-07-20 | 1999-07-20 | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1098974A2 (en) |
JP (1) | JP2002522019A (en) |
AU (1) | AU5081899A (en) |
CA (1) | CA2335326A1 (en) |
WO (1) | WO2000005369A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003078648A2 (en) * | 2002-03-11 | 2003-09-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
US8153586B2 (en) | 1996-10-16 | 2012-04-10 | Zymogenetics, Inc. | FGF homologs compositions and uses thereof |
US8507430B2 (en) | 2002-10-07 | 2013-08-13 | Zymogenetics, Inc. | Methods for administering FGF18 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012084561A (en) * | 2010-10-06 | 2012-04-26 | Fujitsu Semiconductor Ltd | Semiconductor device and method of manufacturing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2106550A (en) | 1980-09-15 | 1983-04-13 | Nuovo Pignone Spa | Weft transfer devices in shuttleless looms |
EP0123005B1 (en) | 1983-04-18 | 1986-09-17 | Maschinenfabrik Sulzer-Rüti Ag | Gripper for inserting a weft thread into a gripper weaving machine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4091122B2 (en) * | 1996-10-16 | 2008-05-28 | ザイモジェネティクス,インコーポレイティド | Fibroblast growth factor homolog |
US6057435A (en) * | 1997-09-19 | 2000-05-02 | Genentech, Inc. | Tie ligand homologues |
WO1999040193A1 (en) * | 1998-02-04 | 1999-08-12 | Zymogenetics, Inc. | Angiopoietin homolog zapo3, dna encoding it, and method of making it |
-
1999
- 1999-07-20 WO PCT/US1999/012839 patent/WO2000005369A2/en not_active Application Discontinuation
- 1999-07-20 CA CA002335326A patent/CA2335326A1/en not_active Abandoned
- 1999-07-20 EP EP99935312A patent/EP1098974A2/en not_active Withdrawn
- 1999-07-20 JP JP2000561315A patent/JP2002522019A/en not_active Withdrawn
- 1999-07-20 AU AU50818/99A patent/AU5081899A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2106550A (en) | 1980-09-15 | 1983-04-13 | Nuovo Pignone Spa | Weft transfer devices in shuttleless looms |
EP0123005B1 (en) | 1983-04-18 | 1986-09-17 | Maschinenfabrik Sulzer-Rüti Ag | Gripper for inserting a weft thread into a gripper weaving machine |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8153586B2 (en) | 1996-10-16 | 2012-04-10 | Zymogenetics, Inc. | FGF homologs compositions and uses thereof |
US8349590B2 (en) | 1996-10-16 | 2013-01-08 | Zymogenetics, Inc. | FGF homologs compositions and uses thereof |
WO2003078648A2 (en) * | 2002-03-11 | 2003-09-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
WO2003078648A3 (en) * | 2002-03-11 | 2004-11-25 | Curagen Corp | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
US8507430B2 (en) | 2002-10-07 | 2013-08-13 | Zymogenetics, Inc. | Methods for administering FGF18 |
Also Published As
Publication number | Publication date |
---|---|
JP2002522019A (en) | 2002-07-23 |
CA2335326A1 (en) | 2000-02-03 |
EP1098974A2 (en) | 2001-05-16 |
WO2000005369A3 (en) | 2000-06-15 |
AU5081899A (en) | 2000-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5607918A (en) | Vascular endothelial growth factor-B and DNA coding therefor | |
US6689580B1 (en) | Growth factor | |
KR100728405B1 (en) | Nucleotide and protein sequences of nogo genes and methods based thereon | |
EP0750628B1 (en) | Fibroblast growth factor-10 | |
JP3492999B2 (en) | Homologs of adipocyte-specific proteins | |
JPH10510718A (en) | Vascular endothelial growth factor-B | |
JP2002523035A (en) | 49 human secreted proteins | |
JP2003159083A (en) | New neurotrophic factor | |
JP2002509432A (en) | Mammalian cytokine-like factor 7 | |
JP2002532083A (en) | 47 human secreted proteins | |
JP2002506625A (en) | Cytokine receptor common γ chain-like | |
JP2002530062A (en) | 12 human secreted proteins | |
JP2002540763A (en) | 33 human secreted proteins | |
JP2002505871A (en) | 31 human secretory proteins | |
WO1999032515A2 (en) | Angiopoietin homolog, dna encoding it, and method of making it | |
EP0962530A2 (en) | Gene sequence encoding for the angiopoietin related protein scarface 1 | |
WO2000005369A2 (en) | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis | |
US6537554B1 (en) | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis | |
US20030104573A1 (en) | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis | |
JPH11507504A (en) | Fibroblast growth factor 13 | |
JP2000515726A (en) | Polynucleotide derived from adult PBMC encoding secreted protein | |
JP2002530058A (en) | 31 human secretory proteins | |
KR20010043090A (en) | NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF | |
EP0962466A1 (en) | Angiopoietin related gene sequence scarface 3 | |
JP2002504361A (en) | 36 human secreted proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase in: |
Ref document number: 2335326 Country of ref document: CA |
|
ENP | Entry into the national phase in: |
Ref country code: JP Ref document number: 2000 561315 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999935312 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 50818/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09744184 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999935312 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999935312 Country of ref document: EP |